Novogene Co., Ltd. (SHA:688315)
17.00
+1.99 (13.26%)
Jan 23, 2026, 3:00 PM CST
Novogene Market Cap
Novogene has a market cap or net worth of 6.08 billion as of January 23, 2026. Its market cap has increased by 15.82% in one year.
Market Cap
6.08B
Enterprise Value
4.64B
Revenue
2.17B
Ranking
n/a
PE Ratio
34.85
Stock Price
17.00
Market Cap Chart
Since April 13, 2021, Novogene's market cap has decreased from 10.97B to 6.08B, a decrease of -44.55%. That is a compound annual growth rate of -11.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 22, 2026 | 6.08B | 13.03% |
| Dec 31, 2025 | 5.38B | 6.24% |
| Dec 31, 2024 | 5.06B | -47.88% |
| Dec 29, 2023 | 9.71B | -8.02% |
| Dec 30, 2022 | 10.56B | -36.10% |
| Dec 31, 2021 | 16.53B | 50.73% |
| Apr 13, 2021 | 10.97B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Kexing Biopharm | 6.72B |
| R&G PharmaStudies | 6.72B |
| Xiangxue Pharmaceutical | 6.67B |
| Shanghai OPM Biosciences | 6.43B |
| PharmaResources (Shanghai) | 6.38B |
| Hangzhou Biotest Biotech | 5.98B |
| Shenzhen Weiguang Biological Products | 5.96B |
| Wuhan Hvsen Biotechnology | 5.95B |